Jenoptik (JEN) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Revenue rose 7.1% year-over-year to €540.8m in H1 2024, with double-digit earnings growth and improved profitability, mainly driven by Advanced Photonic Solutions and Non-Photonic Portfolio Companies.
Q2 2024 saw a strong rebound in order intake, especially in semiconductor equipment, though H1 order intake remained below the prior year.
EBITDA increased 10.7% to €101.4m, with margin up to 18.8% from 18.1% year-over-year.
Earnings per share rose to €0.69, up 23% quarter-over-quarter and year-over-year.
Construction of the new Dresden fab is progressing on schedule, supporting future growth.
Financial highlights
H1 2024 order intake: €524.4m, down 4.1% year-over-year, but Q2 showed a strong rebound; order backlog at €734.1m.
Group revenue up 7.1% year-over-year in H1, driven by APS and Non-Photonic Portfolio Companies.
Group EBITDA reached €101.4m, margin up 70 bps to 18.8%, mainly from scale effects.
Free cash flow before interest and tax rose 58.6% to €41.5m.
Net debt at €429.6m; leverage stable at 2.0x EBITDA; equity ratio at 54.2%.
Outlook and guidance
Full-year 2024 guidance confirmed: mid-single-digit sales growth and EBITDA margin of 19.5–20%, including a 0.5pp negative impact from Dresden fab move.
H2 order intake expected to exceed H1, with strong backlog supporting 2024 targets.
CapEx for 2024 expected slightly above previous year, with catch-up in H2 due to phasing.
Margin expected to remain flat in H2 due to strong prior-year comps and increased personnel costs.
Guidance assumes stable political and economic conditions; portfolio changes not included.
Latest events from Jenoptik
- Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025